These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25986264)

  • 1. Acute Renal Injury Induced by Hypersensitivity to Tolvaptan in an Elderly Patient with Congestive Heart Failure.
    Yamaguchi M; Nishihira K; Okubo T; Asada Y; Kitamura K
    Intern Med; 2015; 54(10):1243-6. PubMed ID: 25986264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case report with shock induced by tolvaptan in an elderly patient with congestive heart failure.
    Zhang ZG; Liu XM
    Medicine (Baltimore); 2018 Jan; 97(1):e8706. PubMed ID: 29505505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
    Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.
    Urbach J; Goldsmith SR
    Ther Adv Cardiovasc Dis; 2021; 15():1753944720977741. PubMed ID: 33435837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case with recovery of response to tolvaptan associated with remission of acute kidney injury and increased urine osmolality.
    Imamura T; Kinugawa K; Kato N; Minatsuki S; Muraoka H; Inaba T; Maki H; Shiga T; Hatano M; Hosoya Y; Takahashi M; Yao A; Kyo S; Ono M; Komuro I
    Int Heart J; 2013; 54(2):115-8. PubMed ID: 23676373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.
    Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y;
    Int Heart J; 2015; 56(2):213-8. PubMed ID: 25740399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH).
    Higashi K; Murakami T; Ishikawa Y; Itoi T; Ohuchi H; Kodama Y; Honda T; Masutani S; Yamazawa H; Senzaki H; Ishikawa S
    Int J Cardiol; 2016 Feb; 205():37-42. PubMed ID: 26710331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study.
    Minami S; Hamano T; Iwatani H; Mizui M; Kimura Y; Isaka Y
    Clin Exp Nephrol; 2018 Jun; 22(3):550-561. PubMed ID: 29052786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction.
    Imamura T; Kinugawa K
    Int Heart J; 2016 Sep; 57(5):600-6. PubMed ID: 27581675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
    Li L; Bai H; Zhu WL;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):936-40. PubMed ID: 22321279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.
    Kiuchi S; Ikeda T
    Intern Med; 2019 Feb; 58(4):471-475. PubMed ID: 30210135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of tolvaptan in patients with hyponatremia due to heart failure: initial experience.
    Rodríguez-de Muñoz YM; Sánchez-Lázaro IJ; Almenar-Bonet L; Martínez-Dolz L; Rodríguez-Serrano M; Salvador-Sanz A
    Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):319-21. PubMed ID: 24775629
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
    Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM
    J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.
    Imamura T; Kinugawa K; Shiga T; Kato N; Muraoka H; Minatsuki S; Inaba T; Maki H; Hatano M; Yao A; Kyo S; Nagai R
    Circ J; 2013; 77(2):397-404. PubMed ID: 23131721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.
    Imamura T; Kinugawa K
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
    J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.
    Rangasetty UC; Gheorghiade M; Uretsky BF; Orlandi C; Barbagelata A
    Expert Opin Investig Drugs; 2006 May; 15(5):533-40. PubMed ID: 16634691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure.
    Shimizu K; Doi K; Imamura T; Noiri E; Yahagi N; Nangaku M; Kinugawa K
    Nephrology (Carlton); 2015 Jun; 20(6):405-12. PubMed ID: 25619790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.